Non-invasive therapeutic ultrasound devices used to accelerate drug delivery and deliver perfusion therapy for stroke and peripheral thrombosis. Acquired privately in 2003.
300 Brickstone Square
Massachusetts, United States
|Investor||Investor Type||Location||Participating Rounds|
|Newark, California, United States||Acquired||Carbylan Therapeutics is a clinical-stage, specialty, pharmaceutical company focused on the development and commercialization of proprietary combination therapies that address significant unmet medical needs. The company's initial focus is on the development of Hydros-TA, their proprietary, intra-articular injectable product candidate to treat pain associated with osteoarthritis of the knee. Carbylan Therapeutics previously traded on the Nasdaq Stock Market under the ticker CBYL.||Login to see details|
|Bothell, Washington, United States||Acquired||EKOS develops clinical application of ultrasound accelerated thrombolysis for the treatment of vascular thrombosis and dissolution of thrombus.||Login to see details|
|Title||Application Date||Patent Date||Status
(Patent / Application)